--- title: 'Director, Pricing, Payer Contracting & Analytics at Genetix Biotherapeutics' canonical: 'https://feeny.ai/job/director-pricing-payer-contracting-analytics-genetix-biotherapeutics-somerville-qv5w015kka01' type: 'job' last_seen: '2026-10-19' --- # Director, Pricing, Payer Contracting & Analytics at Genetix Biotherapeutics - **Company:** Genetix Biotherapeutics - **Location:** Somerville, MA - **Compensation:** $216k–$265k - **Posted:** 2026-10-06 - **Last confirmed live:** 2026-10-19 - **Apply:** https://job-boards.greenhouse.io/genetixbiotherapeutics/jobs/8258352 ## Job description ## About Genetix Biotherapeutics At Genetix Biotherapeutics every role has meaning, every team member is respected, and every day is a chance to make a difference. When you join Genetix, you're not just landing a new role, you become part of a company that's pursuing curative gene therapies to give patients and their families more days. We are doers, thinkers and collaborators who embrace and live by our values: Our innovation is rooted in the diversity of our teams and results are achieved through cooperation and the integration of multiple viewpoints. This is personal and we approach every challenge with radical care. This is a full-time hybrid position based in our Somerville, Massachusetts (Assembly Row) office, with an onsite presence required three days per week. Candidates must reside within a commutable distance of the office to be considered. Summary Genetix Biotherapeutics Market Access, Advocacy & Policy team (MAAP) is focused on helping patients access our therapies to deliver on our mission to transform lives through curative therapies for patients with rare, genetic diseases. This committed group is looking for our newest team member to enable authentic, collaborative engagement with the stakeholders and communities that we serve and to support operations across Market Access. Come work with a dedicated, expert group of employees and contribute to a purpose-driven organization that is shaping the future of gene therapy. ## RESPONSIBLITIES The Director of Pricing, Payer Contracting & Analytics is an individual contributor role within Market Access, with broad ownership across payer contracting, including outcomes-based agreements, government pricing, and analytics. This person is the operational and strategic lead for the company's payer contract portfolio and is accountable for a set of functions that are compliance-sensitive, deadline-driven, and both strategically and operationally complex. This role requires detailed management and execution, while thinking strategically about contracting and access in a competitive and evolving market. A highly cross-functional position that interfaces regularly with Finance, Legal, Field Payer Team, Patient Services & Channel Operations, payers, external vendor partners and leadership. Pricing and Payer Contracting - Manage payer contracts for gene therapy portfolio for both commercial and government payers and across all stages of the contract lifecycle, including collaboration with cross-functional partners, external stakeholders and legal counsel - Serve as the internal subject matter expert on contract terms, payer-specific dynamics, and therapy-specific outcomes to support collaboration with Field Payer Team, Legal, Finance, external vendor partners and leadership - Develop contracting strategies and pricing scenario analysis in response to changes in the treatment and payer landscape - Oversee compliance of contracts across payer types, including monitoring performance, addressing disputes, and ensuring terms are met Government Price Reporting - Own regular government price reporting obligations in collaboration with third-party vendors and Finance - Manage pricing events and ensure timely, accurate submissions in compliance with federal and state regulations - Maintain internal documentation to support compliance and audit readiness Analytics - Own payer coverage policy landscape analyses for internal teams and external partners - Lead payer rebate validation and adjudication, across vendors and internal teams, with accountability for accuracy and support on rebate liabilities and exposure - Develop and execute gross-to-net modeling, and ad-hoc analytical requests from Finance and leadership Vendor Management - Manage vendor relationships, holding vendors accountable to timelines and deliverables, and escalating issues as needed - Oversee current vendor workstreams spanning market access strategy and operations - Coordinate vendor activities with cross-functional internal teams to support ongoing business needs ## Qualifications Experience: - 8+ years of experience in pricing, market access, and payer contracting strategy within the pharmaceutical or biotech industry, including strategy consulting experience - Expertise in coverage, access and reimbursement for specialty pharmaceuticals; rare disease, cell and gene therapy and/or hospital-based product experience a plus - Demonstrated experience managing a payer contract portfolio, including contract negotiation, compliance monitoring, and cross-functional support; value-based contracting experience a plus. - Working knowledge of pricing mechanics, including AMP, Best Price, ASP, and government price reporting requirements; hands-on experience preferred - Strong business acumen with experience in financial modeling, rebate adjudication and/or pricing analysis - Experience managing external vendors and coordinating across multiple workstreams simultaneously Skills & Competencies: - Strong sense of urgency, accountability, and patient-centric focus. - Excellent verbal and written communication with high emotional intelligence and active listening. - Strong quantitative and qualitative analytical, investigative, and critical thinking skills with ability to translate insights into action. - Ability to work independently and manage a high volume of complex, ongoing responsibilities - Ability to navigate sensitive information with discretion and strict adherence to compliance standards. - Proficiency in Microsoft Excel, Word, PowerPoint, and data entry systems. Education: - Bachelor’s degree required (preferred fields: Business, Finance, Healthcare Administration, Life Sciences). Relevant advanced degree a plus. Other Requirements: - Ability to work effectively in a fast-paced, evolving environment with competing priorities. - Willingness to travel as needed. Additional Information The pay transparency range provided below is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. We may ultimately pay more or less than the posted range, and the range may be modified in the future. This role is eligible for an annual bonus and long-term incentive. Actual base salary pay will be based on several factors, including but not limited to experience, skills, relevant education/qualifications, external market, internal equity, and other job-related factors permitted by law. Genetix’s total rewards package also provides employees with a comprehensive and competitive benefits suite to support a variety of employee needs. These benefits include comprehensive health, life and disability insurance, employer-matched 401(k) plan, lifestyle spending account, flexible time-off + paid holidays and winter holiday period, tuition reimbursement & loan repayment assistance, paid parental leave, paid onsite parking, commuter subsidy, and much more. Pay Transparency $216,000—$265,000 USD Genetix is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, veteran status or any other applicable legally protected characteristics. ## About Genetix Biotherapeutics ## Company Overview - **One-liner**: Genetix Biotherapeutics (formerly bluebird bio) is a commercial-stage biotechnology company dedicated to developing and delivering one-time, curative genetic therapies for patients with severe rare genetic diseases. - **Entity Type**: Private (taken private in June 2025 after a sale to new ownership) - **Headquarters**: Somerville, Massachusetts, USA (with a presence in the Netherlands) - **Founded**: 1992 (founded as Genetix Pharmaceuticals; rebranded to bluebird bio in 2010; rebranded back to Genetix Biotherapeutics in September 2025) - **Founders**: Not publicly disclosed; the company was originally founded as Genetix Pharmaceuticals in 1992. ## Core Business - **Primary Industries**: Biotechnology, Gene Therapy, Rare Disease Therapeutics - **Target Customers**: B2B (healthcare providers, qualified treatment centers, payers/insurers) and B2C (patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy) - **Mission**: "To transform lives through curative therapies for patients with rare, genetic diseases." ## Products & Services - **LYFGENIA™ (lovotibeglogene autotemcel / lovo-cel)**: An FDA-approved, one-time gene therapy for patients 12 years and older with sickle cell disease. It works by adding functional copies of a modified β-globin gene into the patient's own blood stem cells. - **ZYNTEGLO™ (betibeglogene autotemcel)**: An FDA-approved, one-time gene therapy for patients with β-thalassemia who require regular blood transfusions. It adds functional copies of a modified β-globin gene into the patient's own blood stem cells. - **SKYSONA™ (elivaldogene autotemcel)**: An FDA-approved, one-time gene therapy for boys with cerebral adrenoleukodystrophy (CALD), a rare, progressive genetic brain disease. It adds a functional copy of the ABCD1 gene into the patient's own blood stem cells. - **Patient Support Program**: Personalized assistance for patients and families navigating the treatment journey, including insurance questions, treatment center coordination, and one-on-one support. ## Market Standing - **Valuation/Market Cap**: Not publicly disclosed (privately held after take-private transaction in June 2025) - **Key Metrics**: - **Annual Revenue**: Not publicly disclosed (but the company reported strong revenue growth in 2025 and achieved its **first ever profitable quarter** in that year) - **Total Funding**: Not publicly disclosed (new investors provided "significant capital" to support operational objectives following the take-private transaction) - **Notable Investors/Partners**: New ownership group (undisclosed); manufacturing partners include **Minaris**, **Lonza**, and **MilliporeSigma** (the U.S. and Canada business of Merck KGaA, Darmstadt, Germany) - **Growth Signals**: - **2025 commercial performance**: >100 patients treated in the U.S.; >150 patients completed their first cell collection cycle; 70 active Qualified Treatment Centers (QTCs) — the largest network for hemoglobinopathy gene therapies nationwide - **2026 outlook**: Doubling manufacturing capacity by mid-2026; targeting first full year of profitability; expanding LYFGENIA label to pediatric patients <12 years of age; advancing cryopreserved apheresis to improve the treatment experience ## Competitive Advantages - **First-mover & market leader**: The only company with FDA approval for three gene therapies, and the market leader in the U.S. for hemoglobinopathy gene therapies - **Proven commercial model**: >100 patients treated in a single year demonstrates real-world commercial execution and manufacturing scale - **Decades of scientific innovation**: Over 30 years of R&D in genetic therapy, with extensive clinical data from hundreds of treated patients (including 15-year long-term follow-up studies) - **Strong access**: LYFGENIA and ZYNTEGLO have meaningful access for >90% of eligible patients with commercial or Medicaid coverage - **One-time curative approach**: Therapies are designed to treat the underlying cause of disease, offering durable, potentially life-long benefits from a single administration ## Strategic Focus - **Commercial execution & patient access**: Expanding the Qualified Treatment Center network and making the treatment journey simpler for patients and providers - **Manufacturing scale-up**: Doubling manufacturing capacity in 2026 through partnerships with CDMOs to meet growing patient demand - **Process optimization**: Implementing cryopreserved apheresis to improve the patient and provider experience - **Label expansion**: Advancing the HGB-210 Phase 3 study to bring LYFGENIA to pediatric sickle cell patients under 12 years of age - **Full-year profitability**: Targeting the company's first full year of profitability in 2026 ## Why Work Here - **Mission-driven culture**: "United by purpose" — the company is laser-focused on transforming the lives of patients with rare, genetic diseases through curative therapies - **Strong momentum**: Recently achieved first-ever profitable quarter, with rapid commercial growth and a clear plan for expansion in 2026 - **Remote/hybrid policy**: Roles are listed as both on-site (Somerville, MA) and remote (e.g., Account Manager, Gene Therapy) — flexible arrangements appear available depending on the role - **Active hiring**: 23 job postings as of the search date, spanning Commercial, Quality Assurance, Technical Operations, Medical, and Regulatory functions - **Experienced leadership**: Led by CEO David Meek (ex-Mirati Therapeutics, Ipsen) with a seasoned executive team of industry veterans, signaling strong strategic direction - **Notable perks/culture**: High-impact work at the intersection of cutting-edge science and commercial execution; opportunity to join a company in the middle of a dramatic turnaround and growth phase; patient-centric focus with a dedicated support program ## Sources 1. [genetixbiotx.com - Company website](https://www.genetixbiotx.com/) 2. [job-boards.greenhouse.io - Careers page](http://job-boards.greenhouse.io/genetixbiotherapeutics) 3. [linkedin.com - LinkedIn company page](https://www.linkedin.com/company/genetix-biotherapeutics) 4. [genetixbiotx.com - Press release: Rebrand from bluebird bio](https://www.genetixbiotx.com/press-release-2025-09-18.html) 5. [genetixbiotx.com - Press release: 2025 commercial results & 2026 priorities](https://www.genetixbiotx.com/press-release-2026-03-02.html) ## Other roles at Genetix Biotherapeutics - [National Account Executive, West](https://feeny.ai/job/national-account-executive-west-genetix-biotherapeutics-los-angeles-5j8hdvsqn5cg) — Los Angeles, CA - [Sr. Director, Quality Operations](https://feeny.ai/job/sr-director-quality-operations-genetix-biotherapeutics-somerville-traazwk35kj1) — Somerville, MA - [Senior Manager, Quality Assurance Vendor & Audit Management](https://feeny.ai/job/senior-manager-quality-assurance-vendor-audit-management-genetix-sn50jbp7ge60) — Somerville, MA - [National Account Executive, Northeast](https://feeny.ai/job/national-account-executive-northeast-genetix-biotherapeutics-boston-c1rw5debhezz) — Boston, MA - [Process Engineer II](https://feeny.ai/job/process-engineer-ii-genetix-biotherapeutics-somerville-jtx6w2g8h780) — Somerville, MA - [Sr. Manager - IT Commercial and Medical Systems](https://feeny.ai/job/sr-manager-it-commercial-and-medical-systems-genetix-biotherapeutics-somerville-drs30kf4perv) — Somerville, MA - [Sr. Director, Regulatory Strategy](https://feeny.ai/job/sr-director-regulatory-strategy-genetix-biotherapeutics-somerville-fpj4qjceza7s) — Somerville, MA - [Manager, End User Services & Lab Support](https://feeny.ai/job/manager-end-user-services-lab-support-genetix-biotherapeutics-somerville-q2ah951d4k1c) — Somerville, MA - [Paralegal and Legal & Compliance Operations Manager](https://feeny.ai/job/paralegal-and-legal-compliance-operations-manager-genetix-biotherapeutics-m768zfn33tct) — Somerville, MA - [Associate Manager, Quality Assurance Operations](https://feeny.ai/job/associate-manager-quality-assurance-operations-genetix-biotherapeutics-8m008cez8h16) — Somerville, MA